ReachRxResearch
Home
Research
Sign Up
RNA m⁶A modification and its regulatory factors are altered in granulosa cells from women with PMOS
Back to Research Hub
  1. Home
  2. Research Hub
  3. RNA m⁶A modification and its regulatory…

RNA m⁶A modification and its regulatory factors are altered in granulosa cells from women with PMOS

Journal of Assisted Reproduction and Genetics·September 3
Obstetrics & GynecologyLimited evidenceAnovulatory InfertilityPolycystic Ovary SyndromeCase-Control StudyRNA Epigenetics / EpitranscriptomicsAdult

Summary

View source

What was studied

This case-control study examined global m⁶A RNA methylation levels, expression of m⁶A writer/reader/eraser (WRE) genes, and selected microRNAs in granulosa cells (GCs) from 23 women with PCOS (labeled 'PMOS' in this paper) vs. 23 age- and BMI-matched controls undergoing IVF.

Key findings

Global m⁶A was significantly elevated in PCOS GCs; writer (METTL3, METTL14, WTAP, RBM15, VIRMA) and reader (YTHDF1, YTHDF3, YTHDC1) transcripts were upregulated, while eraser transcripts (FTO, ALKBH5) were downregulated. Elevated m⁶A, METTL3, METTL14, and YTHDF1 positively correlated with androgen excess, AMH, and reduced oocyte fertilization rates. miR-20b was downregulated and miR-607 was upregulated.

Study limitations

- The study is observational and cannot establish causality between epitranscriptomic changes and PCOS pathophysiology. - mRNA-level expression of WRE genes was assessed by RT-qPCR without protein-level validation. - Small sample size (n=23 per group) limits generalizability.

Clinical implications

Widespread epitranscriptomic dysregulation—particularly elevated m⁶A and imbalanced writer/eraser expression—in granulosa cells may contribute to impaired folliculogenesis and reduced fertilization in PCOS, but findings are currently foundational and not yet actionable clinically.

Caveats

  • Full text content was not extractable from the PDF (page body was blank); summary is based entirely on the abstract and results/conclusions sections provided.
  • Protein-level validation of WRE gene expression changes is absent; all molecular findings are transcript-level only.
  • The paper uses the term 'PMOS' (Polyendocrine Metabolic Ovarian Syndrome) rather than the standard 'PCOS' (Polycystic Ovary Syndrome); this appears to be either a novel rebranding or a terminology error — clinicians should be aware this likely refers to PCOS.

Related Questions

Explore related topics

What is the role of METTL3 and m6A modification in granulosa cell function and female fertility?How does FTO or ALKBH5 dysregulation affect ovarian function in PCOS?Are there epitranscriptomic or microRNA biomarkers associated with poor IVF outcomes in PCOS patients?

Publication Details

Year
2026
Journal
Journal of Assisted Reproduction and Genetics
Sample Size
n=46
Source
View article
Keep scrolling
More content below.
Up Next